These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23553067)

  • 21. [Investigation of Administration Technique of Regorafenib in Our Center].
    Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
    Davis LE; Bolejack V; Ryan CW; Ganjoo KN; Loggers ET; Chawla S; Agulnik M; Livingston MB; Reed D; Keedy V; Rushing D; Okuno S; Reinke DK; Riedel RF; Attia S; Mascarenhas L; Maki RG
    J Clin Oncol; 2019 Jun; 37(16):1424-1431. PubMed ID: 31013172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.
    Fujita K; Taguchi D; Fukuda K; Yoshida T; Shimazu K; Shinozaki H; Shibata H; Miura M
    Invest New Drugs; 2024 Jun; 42(3):252-260. PubMed ID: 38517650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
    Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Honda K; Tamura Y; Wakui H; Sasaki T; Yusa W; Fujino K; Tamura T
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1153-61. PubMed ID: 26530955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
    Komatsu Y; Doi T; Sawaki A; Kanda T; Yamada Y; Kuss I; Demetri GD; Nishida T
    Int J Clin Oncol; 2015 Oct; 20(5):905-12. PubMed ID: 25655899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
    Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
    Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
    Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
    Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
    Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI
    Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
    Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
    Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
    Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
    J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
    Agulnik M; Schulte B; Robinson S; Hirbe AC; Kozak K; Chawla SP; Attia S; Rademaker A; Zhang H; Abbinanti S; Cehic R; Monga V; Milhem M; Okuno S; Van Tine BA
    Eur J Cancer; 2021 Sep; 154():201-208. PubMed ID: 34284255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.